{'fraction_non_alphanumeric': 0.03318903318903319, 'fraction_numerical': 0.012987012987012988, 'mean_word_length': 5.547169811320755, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cancer immunotherapy according to GARP.

Immunotherapy
Cancer, like microbes, can adapt to become resistant to a single therapy, making combination therapies the approach of choice. Complementary therapies that decrease immunosuppression may boost the efficacy of immunotherapies. Rachidi et al. found that targeting platelets improved adoptive T cell therapy of multiple cancers in mice. Transforming growth factor β (TGFβ) from platelets decreased T cell function, largely through the expression of the TGFβ docking receptor, GARP (glycoprotein A repetitions predominant). Thus, combining immunotherapy with platelet inhibitors may improve cancer therapy.

Sci. Immunol. 2 , eaai7911 (2017).